CR-8020
Based on 1 Customer Validation
CR-8020 is a broadly neutralizing antibody targeting the stem region of influenza A virus hemagglutinin (HA), with IC50 values of 0.06 nM or 3.36 nM. CR-8020 mediates antibody-dependent cellular cytotoxicity by activating Fcγ receptors. CR-8020 blocks viral fusion and entry. CR-8020 protects mice from lethal influenza A virus challenge. CR-8020 can be used in research related to influenza A virus infections (H3N2 and H7N9).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95%
- CAS 番号: 1422526-93-9
- 分子量:146.434 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
Human IgG1 kappa
Virus
|
Influenza hemagglutinin (HA) |
CR-8020 (0.0001-100 mg/mL) binds with high affinity to H3N2 HA from the A/Wyoming/3/2003 strain (IC50 0.06 nM) and H3N2 HA from the A/Brisbane/10/2007 strain (IC50 3.36 nM), but shows negligible binding to H7N9 HA from the A/Shanghai/02/2013 strain[1].
Most epitope residues of H3N2 and H7N9 HA targeted by CR-8020 are susceptible to sequence drift and host selection pressure, with multiple predicted single-base escape mutations; among these, the D19N escape mutation is present in a circulating H7N9 strain[1].
CR-8020 potently neutralizes and binds to group 2 influenza A virus strains by targeting a highly conserved HA epitope[2].
CR-8020 (1-10000 ng/mL; 6 h) mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in H3N2-infected A549 cells via activation of FcγRIIIa, but its potency is approximately 10-fold lower than that of antibodies targeting the interface of influenza HA trimers[1].
The ternary complexes HA-CR8020-FcγRIIa and HA-CR8020-FcγRIIIa formed by CR-8020 are subject to steric hindrance from viral or cell membranes, which limits the ability of CR8020 to activate FcγRIIa and FcγRIIIa[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified strain[2]
-
Dosage:3 mg/kg
-
Administration:i.n.; every 24 hours; 7 days
-
Result:Conferred protection against lethal challenge of both mouse-adapted H3N2 and H7N9 viruses.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 1422526-93-9
-
性状 Liquid
-
分子量 146.434 kDa
-
Color Colorless to light yellow
-
SMILES
[CR8020]
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Tharakaraman K, et al. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell host & microbe. 2014 May 14;15(5):644-51. [Content Brief]
[2]. Zeng LY, et al. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert opinion on investigational drugs. 2017 Jan;26(1):63-73. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)